Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background & Aims: Tofacitinib and upadacitinib are Janus kinase (JAK) inhibitors that are increasingly used for the treatment of acute severe ulcerative colitis (ASUC). However, comparative analyses of safety and effectiveness have not been performed for their use in this setting.
Methods: This multicenter, retrospective study enrolled hospitalized adult patients treated with tofacitinib or upadacitinib for ASUC between January 2019 and June 2024. The main outcomes were clinical response, clinical remission, and colectomy-free survival. Propensity-adjusted analyses using inverse probability treatment weighting, and double robust estimations were used to control for confounding factors.
Results: In total, 111 patients (60 tofacitinib, 51 upadacitinib) were enrolled across 23 international centers. JAK inhibitors were used to induce response in 86 patients (77%) and used to maintain response after adequate intravenous steroid response in 25 (23%). The median follow up was 31 weeks (interquartile range, 13-64 weeks). Between days 3 and 7 after treatment initiation, upadacitinib was associated with greater response rates (84% vs 54%; P = .02), but response/remission was comparable at day 98 (45%/36% vs 55%/48%) and day 182 (29/29% vs 39/34%). Sub-analyses for JAK inhibitor use as salvage therapy (tofacitinib [n = 35] vs upadacitinib [n = 31]) showed similar effectiveness outcomes across both groups. The probabilities of colectomy-free survival at days 98 and 182 for tofacitinib and upadacitinib were 79% and 75% and 80% and 78%, respectively, with no significant differences in the comparison of survival curves (P = .99). Treatment failure rates (where JAK inhibitors were used to maintain remission) were similar at days 98 and 182. The frequency of adverse events was comparable.
Conclusion: Tofacitinib and upadacitinib appear to have similar effectiveness and safety profiles when used for the treatment of ASUC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2025.07.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biologics and Small-Molecule Therapies in Netherton Syndrome: A Comprehensive Review.
J Dermatol
September 2025
Department of Molecular Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Netherton syndrome (NS) is a rare congenital ichthyosis caused by loss-of-function mutations in the SPINK5 gene, leading to defective expression of the serine protease inhibitor LEKTI. Dysregulated epidermal protease activity results in impaired skin barrier function and chronic inflammation, accompanied by complex immune profiles. NS patients commonly show activation of the inflammatory axis, centered on IL-17 and IL-36, in the skin and blood, and show a psoriasis-like shift to Th17.
View Article and Find Full Text PDFSystematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases.
Inflamm Bowel Dis
August 2025
Division of Gastroenterology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States.
Background: The systematic review and meta-analysis (SRMA) evaluates the safety and effectiveness of combining biologics and/or small molecules in treating refractory inflammatory bowel diseases (IBD).
Methods: Our 2022 SRMA identified 13 studies published until November 3, 2020. An updated systematic search was completed from May 2020 through January 31, 2024.
The Role of Upadacitinib in Refractory Dermatomyositis: A Systematic Review.
J Am Acad Dermatol
August 2025
Department of Dermatology, Wayne State University, Detroit, MI, USA.
Real‑world safety and efficacy of biological agents in inflammatory bowel disease: a one-year post-marketing pharmacovigilance observational study in the Calabria region.
Pharmacol Rep
August 2025
Department of Health Sciences, Magna Graecia University of Catanzaro, Catanzaro, 88100, Italy.
Background: The use of immune-modifying biological agents has markedly changed the clinical course and the management of inflammatory bowel diseases (IBDs). Active post-marketing surveillance programs are essential for the early recognition of both expected and unexpected adverse events (AEs), providing a powerful tool for better defining the safety profiles of biologics in a real-world setting.
Methods: Patients diagnosed with IBDs and treated with biologic drugs at two gastroenterology units in Calabria, Italy, were monitored during the period from 2023 to 2024.
Clinical Characteristics and 1-Year Response in Rheumatic Mexican Patients Using JAK Inhibitors: Data From BIOBADAMEX.
J Clin Rheumatol
August 2025
Facultad de Medicina y Ciencias Biomédicas, Universidad Autónoma de Chihuahua, Chihuahua, México.
Objective: We aim to evaluate the clinical features, first-year treatment response, and frequency of adverse events in Mexican patients receiving Janus kinase inhibitor (JAK-i) using data from the Mexican Adverse Events Registry (BIOBADAMEX).
Methods: We included all BIOBADAMEX patients from 2022 to 2024 and described the sociodemographic, clinical, treatment characteristics and adverse events of the approved JAK-i in Mexico: tofacitinib, baricitinib, and upadacitinib. We assessed the JAK-i efficacy comparing baseline and the 1-year response mean disease activity scores.